RXi Pharmaceuticals to Present at Biotech Showcase™ 2013

  RXi Pharmaceuticals to Present at Biotech Showcase™ 2013

Biotech Showcase 2013

Business Wire

WESTBOROUGH, Mass. -- December 19, 2012

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused
on discovering, developing and commercializing innovative therapies addressing
major unmet medical needs using RNA-targeted technologies, today announced
that the Company’s President and Chief Executive Officer, Dr. Geert
Cauwenbergh, will present at the Biotech Showcase™ 2013 Conference on Tuesday,
January 8, 2013 at 9:30AM PT. Dr. Cauwenbergh will discuss the development of
RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring,
as well as business development opportunities with RXi’s sd-rxRNA® technology
platform.

The presentation will be available on the company’s website at:
http://www.rxipharma.com/resources/

Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech
Showcase is an investor and partnering conference devoted to providing private
and public biotechnology and life sciences companies an opportunity to present
to, and meet with, investors and pharmaceutical executives during the course
of one of the industry’s largest annual healthcare investor conferences. Now
in its fifth year, Biotech Showcase is expected to attract upwards of 1,500
attendees. The meeting will take place January 7-9, 2013 at the Parc 55
Wyndham San Francisco Union Square Hotel, California.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused
on discovering, developing and commercializing innovative therapies based on
its proprietary, self delivering RNAi platform. Therapeutics that use RNA
interference, or “RNAi,” have great promise because of their ability to
down-regulate, the expression of a specific gene that may be over-expressed in
a disease condition. Building on the pioneering work of scientific founder and
Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board,
RXi’s first RNAi product candidate, RXI-109, which targets CTGF, entered into
human clinical development in June 2012. For more information, please visit
www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.Such statements include,
but are not limited to, statements about future expectations, planned and
future development of RXi Pharmaceuticals Corporation’s products and
technologies.Forward-looking statements about expectations and development
plans of RXi’s products involve significant risks, and uncertainties: risks
that RXi may not be able to successfully develop its candidates, or that
development of RNAi-based therapeutics may be delayed or not proceed as
planned, or that we may not develop any RNAi-based product; risks that the
development process for our product candidates may be delayed, risks related
to development and commercialization of products by our competitors, risks
related to our ability to control timing and terms of collaborations with
third parties, and the possibility that other companies or organizations may
assert patent rights preventing us from developing our products.Actual
results may differ from those contemplated by these forward-looking
statements.RXi does not undertake to update forward-looking statements to
reflect a change in its views, events or circumstances that occur after the
date of this release.

Contact:

RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com
 
Press spacebar to pause and continue. Press esc to stop.